Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation safeguards vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to generate defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.

• Nearly 85% protection when immunised four weeks before birth
• Antibodies from the mother passed through placenta protect newborns from birth
• Protection possible with 2-week gap before premature birth
• Vaccination during third trimester still provides significant protection for infants

Strong evidence from the latest research

The effectiveness of the RSV vaccine administered during pregnancy has been established through a extensive research programme conducted across England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s conclusions have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation gives healthcare professionals and expectant parents with trust in the vaccine’s proven efficacy across diverse populations and circumstances.

The results reveal a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.

Research approach and coverage

The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology measured real-world outcomes rather than experimental conditions, providing practical evidence of how the vaccine functions when administered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and the hazards

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection produces deep inflammation in the lungs and airways, making it perilously hard for affected infants to feed and breathe effectively. Parents frequently observe their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their damaged lungs. Whilst most infants get better with clinical support, a modest yet notable number die from RSV complications each year, making vaccination as prevention a essential public health imperative for defending the youngest and most at-risk individuals in the population.

• RSV produces lung inflammation, leading to severe breathing difficulties in infants
• Approximately half of newborns contract the virus during their first few months alive
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
• Over 20,000 UK infants require serious hospital care for RSV each year
• A small number of babies die from RSV complications each year in the UK

Adoption rates and specialist advice

Since the RSV vaccine programme launched in 2024, health officials have emphasised the importance of pregnant women getting their jab at the best time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the most robust immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.

The guidance from public health bodies remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection irrespective of geographical location.

• NHS trusts deploying multiple messaging strategies to engage with pregnant women
• Regional disparities in vaccination coverage levels throughout England necessitate strategic intervention
• Regional health providers adapting programmes to align with specific population needs

Real-world impact and parental perspectives

The vaccine’s impressive effectiveness provides concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this preventative solution, the 80% drop in admissions means thousands of infants protected against critical disease. Parents no longer face the upsetting situation of seeing their babies struggle for breath or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the landscape of neonatal breathing health, providing expectant mothers a active means to safeguard their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s availability carries deep personal significance. His mother’s support of the jab underscores the transformative consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their final trimester, converting what was once an predictable seasonal threat into a manageable health risk.